Immunology startup GentiBio signs $1.9B deal with Bristol Myers


At just two years old, immunology startup GentiBio has signed a collaboration deal with a major pharmaceutical player — to the tune of up to $1.9 billion.

Previous Dentsply Sirona exec leaving as internal probe of financial irregularities expands
Next One Southern Indiana targets future growth, collaboration